One of the most unexpected investing stories of 2026 sits at the crossroads of two booming industries: weight-loss drugs and beauty. The explosive rise of GLP-1 medications (like Ozempic and Zepbound), now a global drug market worth an estimated $50 billion a year, is having surprising ripple effects across skincare and aesthetics, and it's quietly creating a whole new investing theme.
This post explains the "Ozempic effect" on beauty, which parts of the industry it's driving, the listed companies investors are researching, and the honest risks of investing around such a young trend. It's about industry and market trends, not medical advice. If it leaves you wanting to explore the stocks, you can do that from just $1 with zero commission on the Nemo.money app.
Investors around the world are searching:
- "Ozempic effect beauty stocks"
- "How are weight-loss drugs affecting beauty?"
- "Galderma stock"
- "GLP-1 skincare companies"
- "Which stocks benefit from Ozempic?"
What Is the "Ozempic Effect" on Beauty?
GLP-1 drugs help people lose weight rapidly, and that speed has an unexpected consequence for appearance. Fast, medically-driven weight loss can cause facial volume loss, skin laxity and other changes, a phenomenon widely nicknamed "Ozempic face."
With tens of millions of people now using these medications (an estimated 31 million Americans, by one survey), that's created a large and growing group of consumers seeking solutions, and beauty and aesthetics companies are racing to serve them.
Where the Demand Is Flowing
The "Ozempic effect" is showing up across several parts of the beauty and wellness industry:
- 🧴 Medical-grade skincare. Brands are launching serums and treatments aimed at restoring firmness and volume, targeting the specific concerns of GLP-1 users. One consultancy dubbed this the "GLP-1 Halo Effect," naming it a key trend to watch.
- 💉 Aesthetic treatments (injectables). Demand for fillers, collagen stimulators and similar treatments has climbed. One major aesthetics company, Galderma, reported record first-half 2026 sales of around $3.1 billion, up roughly 25% year on year, with growth partly linked to this trend.
- 🧪 Specialist ingredients. Even ingredient suppliers are seeing renewed interest in "actives" that plump and firm skin, one heritage ingredient reportedly saw demand accelerate on the back of the trend.
- 💊 Nutricosmetics and wellness. Collagen supplements and "beauty-from-within" products aimed at supporting skin during weight loss are another emerging area.
The through-line: a blockbuster trend in pharmaceuticals is generating brand-new demand in beauty and aesthetics, a striking example of how themes ripple across sectors in ways investors don't always anticipate.
Why This Matters for Investors
The "Ozempic effect" is a useful lesson in second-order thinking, looking beyond the obvious winner (the drugmakers) to the knock-on beneficiaries:
- 🔗 Cross-sector ripples. The most direct GLP-1 beneficiaries are pharma companies, but the trend also touches aesthetics, skincare, ingredients, even food and apparel. Second-order effects can create opportunities the headlines miss.
- 🌍 A structural, not seasonal, driver. If GLP-1 use keeps growing, the associated skincare and aesthetics demand could be a multi-year theme rather than a passing fad, though that's a big "if."
- 🧬 Innovation magnet. The trend is pushing beauty companies toward more science-driven, "medical-grade" products, which can support premium pricing.
The Beauty & Pharma Stocks
Investors research this theme across several groups. All of the below are examples to research, not recommendations, and many are large, diversified companies for which GLP-1 is only a small part of the story.
Aesthetics and injectables (fillers, collagen stimulators, botulinum toxin, the most direct beauty-side beneficiaries):
- Galderma (SIX: GALD), the pure-play dermatology and injectables leader (Restylane, Sculptra, Dysport). Swiss-listed.
- AbbVie (NYSE: ABBV), which owns Allergan Aesthetics, the maker of Botox and Juvéderm.
Prestige and mass beauty (expanding into medical-grade and "longevity" skincare):
- Estée Lauder (NYSE: EL)
- L'Oréal (US OTC: LRLCY; Paris: OR), which is also increasing its stake in Galderma
- e.l.f. Beauty (NYSE: ELF), Ulta Beauty (NASDAQ: ULTA) and Coty (NYSE: COTY)
Specialist ingredients (the "actives" behind plumping and firming products):
- Croda International (LSE: CRDA), UK-listed.
The GLP-1 drugmakers themselves (the first-order play, a different, pharma-focused investment with its own risks):
- Novo Nordisk (NYSE: NVO), maker of Ozempic and Wegovy
- Eli Lilly (NYSE: LLY), maker of Mounjaro and Zepbound
Broad exposure: consumer, healthcare or thematic ETFs that hold a basket of relevant names.
A quick, honest note on the tickers: the US-listed names (EL, ELF, ULTA, COTY, ABBV, NVO, LLY, and L'Oréal's LRLCY) are the most accessible to many investors; Galderma (Switzerland) and Croda (UK) are non-US listings that may not be available on every platform.
The Honest Risks (This Is a Young Theme)
This is genuinely exciting, but it comes with real caveats, arguably more than most themes, because it's so new:
- ⚠️ It's early and unproven. The "Ozempic effect" on beauty is a recent, fast-evolving trend. How much it ultimately moves revenue for any specific company is far from certain.
- ⚠️ A trend is not a stock. Even if the theme is real, that doesn't mean a given company will benefit, or that its shares are well-priced today. Many of these firms are large and diversified, so GLP-1 is only a small part of the story.
- ⚠️ Hype risk. Buzzy, headline-friendly themes can get over-hyped, pulling in money and inflating valuations before the fundamentals catch up (or fail to).
- ⚠️ It depends on the drugs' trajectory. The theme rests on continued GLP-1 adoption, which could be affected by cost, access, side effects, regulation or newer treatments.
- ⚠️ Regulatory and reputational factors. Medical-grade beauty and aesthetics sit close to healthcare, with the added scrutiny that brings.
How to Explore These Stocks with Nemo.money
If the theme interests you, the Nemo.money app lets you explore the listed players:
- Invest from Just $1: Fractional shares let you start small with eligible stocks and ETFs.
- Zero-Commission Trading: Buy and sell eligible US-market stocks and ETFs without commission fees.
- AI-Powered Insights & Nemes: Explore curated, themed stock collections (Nemes), including consumer and healthcare-linked names, with real-time data and sentiment.
- Earn on Idle Cash: Earn 6% AER interest, paid daily in USD, on uninvested cash in your wallet.
Frequently Asked Questions (FAQs)
What is "Ozempic face"?
"Ozempic face" is a nickname for the facial volume loss, skin laxity and gaunt appearance that can follow rapid weight loss from GLP-1 drugs like Ozempic. Because fat loss happens quickly, the face can lose fullness, prompting some people to seek skincare or aesthetic treatments to restore volume and firmness. This is general information, not medical advice.
How are GLP-1 drugs affecting the beauty industry?
Rapid weight loss from GLP-1 medications has created demand for products and treatments that address facial volume loss and skin laxity, from medical-grade skincare and plumping serums to injectables like fillers and collagen stimulators. Some aesthetics companies have reported strong growth partly linked to this trend, and analysts have flagged a "GLP-1 Halo Effect" as one to watch. It's an early-stage theme, and this is industry information, not medical advice.
Which companies benefit from the "Ozempic effect" in beauty?
Potential beneficiaries include aesthetics and injectables companies (such as Galderma (SIX: GALD) and AbbVie (NYSE: ABBV), which owns Botox-maker Allergan), prestige and mass beauty firms moving into medical-grade skincare (such as Estée Lauder (NYSE: EL) and L'Oréal (LRLCY)), and ingredient suppliers (such as Croda (LSE: CRDA)). The GLP-1 drugmakers themselves, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY), are the first-order beneficiaries. All are examples to research, not recommendations, and your capital is at risk.
Is the GLP-1 beauty trend a good investment theme?
It's a genuinely interesting theme, but a young and unproven one, and this isn't advice. Even if the trend is real, it doesn't guarantee any specific company will benefit meaningfully or that its shares are well-priced. Many potential beneficiaries are large, diversified firms for which GLP-1 is only a small factor. Buzzy themes also carry hype risk. Research the businesses, not just the story. Your capital is at risk.
How can I invest in the "Ozempic effect" beauty theme?
Most investors explore the theme through listed beauty, aesthetics, ingredient or pharma companies, or through thematic consumer/healthcare ETFs that hold a basket of names rather than a single stock. Apps like the Nemo.money app let you research and invest in beauty and Pharma stocks and ETFs from just $1 with zero commission.
Final Thoughts: A Fascinating Ripple, Not a Sure Thing
The "Ozempic effect" on beauty is one of the most intriguing second-order stories in the market right now, a reminder that a blockbuster trend in one industry can create brand-new demand in another. For investors, that makes it a genuinely interesting theme to understand and follow.
But interesting is not the same as investable-at-any-price. This is a young, fast-moving trend layered on top of large, diversified companies, and a compelling story never guarantees a well-priced stock. Explore it with curiosity, keep the double lens of "not medical advice, not investment advice" firmly in mind, and let the fundamentals, not the buzz, drive any decision.
Explore eligible US-listed stocks from $1 with zero commission on the Nemo.money app.
Nemo = Never Miss Out.
Stay informed. Stay ahead.
#Ozempic #GLP1 #BeautyStocks #Investing #NemoMoney
This is not investment advice. Past performance is not indicative of future results. Your capital is at risk. See website for Risk Disclosure. Exinity ME Ltd (https://nemo.money) is regulated by ADGM's Financial Services Regulatory Authority.
